查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
FLT3抑制剂的全球市场:各商品化的治疗方法、潜在的开发中产品、地区 - 分析与预测(2022年～2032年)
市场调查报告书
商品编码
1118293

FLT3抑制剂的全球市场:各商品化的治疗方法、潜在的开发中产品、地区 - 分析与预测(2022年～2032年)

FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential Pipeline Product, and Region - Analysis and Forecast, 2022-2032
出版日期: | 出版商: BIS Research | 英文 152 Pages | 商品交期: 1-5个工作天内

价格

全球FLT3抑制剂的市场规模，从2021年的4亿90万美元到2032年达到20亿6,130万美元，在2022年～2032年的预测期间内预计以14.88％的年复合成长率成长。

由于新产品的引进，急性骨髓性白血病的发生率增加，研究开发投资的高涨等，预计促进市场成长。

本报告提供全球FLT3抑制剂市场相关调查分析，市场动态，市场区隔分析，地区分析，企业简介等资讯。

目录

第1章 市场

  • 产品定义
  • 市场范围
  • 调查手法
  • 市场概要

第2章 产业分析

  • 概要
  • 美国的法律必要条件和架构
  • 欧洲的法律必要条件和架构
  • 日本的法律必要条件和架构
  • 偿付与成本分析

第3章 市场动态

  • 概要
  • 影响分析
  • 推动市场要素
  • 阻碍市场要素
  • 市场机会

第4章 竞争情形

  • 概要
  • 主要的发展与策略
    • 法规与法律上的活动
    • 产品的认证与发售
    • 伙伴关係和合作
    • 其他的发展
  • 市场占有率分析:各企业(2021年)
  • 成长占有率分析

第5章 被全球FLT3抑制剂市场:各商品化的治疗法(2021年～2032年)

  • 概要
  • 第一型FLT3抑制剂
    • XOSPATA(Gilteritinib)
    • Rydapt(Midostaurin)
  • 2型FLT3抑制剂
    • Vanflyta (Quizartinib)

第6章 全球FLT3抑制剂市场:各潜在的开发中产品(2021年～2032年)

  • 概要
  • Crenolanib
  • Dovitinib
  • SKLB1028

第7章 全球FLT3抑制剂市场:各地区(2021年～2032年)

  • 概要
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 义大利
    • 法国
    • 英国
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 日本
    • 中国
    • 其他的亚太地区
  • 其他地区

第8章 企业简介

  • Cullinan Oncology, LLC
  • Astellas Pharma Inc.
  • Allarity Therapeutics, Inc.
  • AROG Pharmaceuticals, Inc.
  • Aptose Biosciences Inc.
  • Novartis International AG
  • Daiichi Sankyo Company, Limited
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • FUJIFILM Pharmaceuticals U.S.A., Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
Product Code: BHL1260SA

“Global FLT3 Inhibitors Market to Reach $2,061.3 Million by 2032.”

Global FLT3 Inhibitors Market: Industry Overview

The global FLT3 inhibitors market is expected to reach $2,061.3 million in 2032 from $400.9 million in 2021 at a CAGR of 14.88% during the forecast period 2022-2032. The global FLT3 inhibitors market growth is expected to be driven by the introduction of novel products, the increasing incidence of acute myeloid leukemia, and the rising research and development investments, among others.

Market Lifecycle Stage

The global FLT3 inhibitors market is in the nascent stage. The landscape of treatment of blood cancers with FLT3 positive mutations by novel inhibitory therapeutics is massively growing, with many emerging and legacy companies venturing into the industry with their respective therapeutic portfolio exclusively developed and designed for the treatment of FLT3 mutated acute myeloid leukemia (AML). Through imaging, genetic, and biomarker studies, researchers are gaining a deeper understanding of the biology of AML, which will likely resolve many current problems in FLT3 mutated AML diagnosis and classification.

The current study aims to assess the global FLT3 inhibitors market by focusing on the marketed and potential pipeline therapies. The current market for FLT3 inhibitors is majorly dominated by pharmaceutical companies such as Novartis International AG, Astellas Pharma Inc., and Daiichi Sankyo Company, Limited. Increasing investments in the research and development of drug manufacturing are one of the major opportunities in the global FLT3 inhibitors market.

Impact

The growing interest of the pharmaceutical industry in the therapeutic potential for treating blood cancers with FLT3 positive mutations has been a catalyst for the progress of the global FLT3 inhibitors market. Recently approved products such as Xospata and Rydapt for treating FLT3 mutated acute myeloid leukemia (AML) The recent increase in the number of drug approvals received for treating acute myeloid leukemia with FLT3 positive mutations is considered to have added value to the emerging potential drug development. There are three FLT3 inhibitors approved by the U.S. Food and Drug Administration during 2015-2021. Also, many FLT3 inhibitors are in preclinical or clinical trials, indicating progress toward making an impact in the pharmaceutical industry.

Drug development is more prominent in countries such as the U.S., Germany, the U.K., and Japan. Moreover, the presence of major market players such as Astellas Pharma Inc., Daiichi Sankyo Company, Limited., Novartis AG, Allarity Therapeutics, Inc., and AROG Pharmaceuticals, Inc. has a positive impact on the market growth.

Market Segmentation

Segmentation 1: by Commercialized Therapies

  • Type 1 FLT3 Inhibitors
  • Type 2 FLT3 Inhibitors

The Type 1 FLT3 inhibitors segment represented the largest market share at 96.63% of total commercialized therapies in 2021. However, the Type 2 FLT3 inhibitors segment is anticipated to register a high growing CAGR of 14.63% during the forecast period 2022-2032.

Segmentation 2: by Potential Pipeline Products

  • Crenolanib
  • Dovitinib
  • SKLB1028

The Dovitinib is expected to hold 59.56% of total potential pipeline products in 2032, while Crenolanib and SKLB1028 segment is expected to hold 33.71% and 6.73% in 2032, respectively.

Segmentation 3: by Region

  • North America - U.S., Canada
  • Europe - Germany, Italy, France, U.K., Spain, Rest-of-Europe
  • Asia-Pacific - China, Japan, Rest-of-APAC (RoAPAC)
  • Rest-of-the-World (RoW)

The North America FLT3 inhibitors market was valued at $252.7 million in 2021, and the region is currently the leading contributor to the market. The growth can be attributed to the increased research and development activities in the region.

Recent Developments in the Global FLT3 Inhibitors Market

  • In March 2021, Astellas Pharma's Xospata (Gilteritinib) met the overall survival endpoint in the COMMODORE trial of subjects having FLT3 mutated relapsed or refractory acute myeloid leukemia.
  • In December 2021, Allarity Therapeutics submitted a New Drug Application (NDA) to the U.S. FDA for Dovitinib as a third-line treatment for renal cell carcinoma (RCC).
  • In June 2021, Cullinan Oncology received Investigational New Drug (IND) Clearance from the FDA for CLN-049 to treat relapsed/refractory AML.
  • In June 2019, Daiichi Sankyo Company, Limited received a Complete Response Letter (CRL) from the U.S. FDA for the New Drug Application (NDA) of Vanflyta (Quizartinib) to treat adult patients with relapsed/ refractory FLT3-ITD acute myeloid leukemia.

Demand - Drivers and Limitations

Following are the demand drivers for the global FLT3 inhibitors market:

  • Introduction of Novel Products
  • Increasing Incidence of Acute Myeloid Leukemia
  • Rising Research and Development Investments

The market is expected to face some limitations too due to the following challenges:

  • High Treatment Cost Impacting the Adoption Rate
  • Disease Relapse in FLT3 Mutated AML

How Can This Report Add Value to an Organization?

  • Product/Innovation Strategy: The product segment helps the reader understand the commercialized therapies present in the market, along with potential pipeline products that are in different stages of clinical trials. Moreover, the study provides the reader with a detailed understanding of regional analysis based on the presence of FLT3 inhibitors.
  • Growth/Marketing Strategy: The global FLT3 inhibitors market has seen major development by key players operating in the market, such as regulatory and legal activities, product approvals and launches, partnerships and alliances, and other development activities. The favored strategy for the companies has been regulatory and legal activities along with product approvals to strengthen their position in the market.
  • Competitive Strategy: Key players in the global FLT3 inhibitors market analyzed and profiled in the study involve drug manufacturers for the treatment of cancer with FLT3 positive mutations. Moreover, a detailed competitive benchmarking of players operating in the global FLT3 inhibitors market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Cullinan Oncology, LLC
  • Astellas Pharma Inc.
  • Allarity Therapeutics, Inc.
  • AROG Pharmaceuticals, Inc.
  • Aptose Biosciences Inc.
  • Novartis International AG
  • Daiichi Sankyo Company, Limited
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • FUJIFILM Pharmaceuticals U.S.A., Inc.
  • Jiangsu HengRui Medicine Co., Ltd.

Table of Contents

1 Market

  • 1.1 Product Definition
    • 1.1.1 Inclusion and Exclusion
  • 1.2 Market Scope
    • 1.2.1 Key Questions Answered in This Report
  • 1.3 Research Methodology
    • 1.3.1 Global FLT3 inhibitors Market: Research Methodology
    • 1.3.2 Data Sources
      • 1.3.2.1 Primary Data Sources
      • 1.3.2.2 Secondary Data Sources
    • 1.3.3 Market Estimation Model
    • 1.3.4 Criteria for Company Profiling
  • 1.4 Market Overview
    • 1.4.1 Introduction
    • 1.4.2 Current Market Size and Growth Potential, $Million, 2021-2032
    • 1.4.3 Types of FLT3 Gene Mutations Involved in AML
      • 1.4.3.1 FLT3-ITD Mutation
      • 1.4.3.2 FLT3-TKD Mutation
    • 1.4.4 Mechanism of FLT3 Inhibitors
    • 1.4.5 Classification of FLT3 Inhibitors
    • 1.4.6 Resistance to AML Therapy Targeted at FLT3
    • 1.4.7 Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
      • 1.4.7.1 Global Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
      • 1.4.7.2 North America Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
      • 1.4.7.3 Europe Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
      • 1.4.7.4 China Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
      • 1.4.7.5 Japan Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
    • 1.4.8 Role of Companion Diagnostics in FLT3 Inhibitors Market
      • 1.4.8.1 Drug-Diagnostic Co-Development
      • 1.4.8.2 Companion Diagnostic Tests for FLT3 Mutated Acute Myeloid Leukemia
        • 1.4.8.2.1 LeukoStrat CDx FLT3 Mutation Assay
        • 1.4.8.2.2 Dovitinib DRP Companion Diagnostic
    • 1.4.9 Pipeline Analysis
      • 1.4.9.1 By Clinical Phase

2 Industry Analysis

  • 2.1 Overview
  • 2.2 Legal Requirements and Frameworks in the U.S.
    • 2.2.1 Clinical Trial Authorization
    • 2.2.2 Marketing Authorization
    • 2.2.3 Post-Authorization Regulations
  • 2.3 Legal Requirements and Frameworks in Europe
  • 2.4 Legal Requirements and Frameworks in Japan
  • 2.5 Reimbursement and Cost Analysis
    • 2.5.1 U.S.
    • 2.5.2 Europe

3 Market Dynamics

  • 3.1 Overview
  • 3.2 Impact Analysis
  • 3.3 Market Drivers
    • 3.3.1 Increasing Incidence of Acute Myeloid Leukemia
    • 3.3.2 Introduction of Novel Products
    • 3.3.3 Rising Research and Development Investments
  • 3.4 Market Restraints
    • 3.4.1 High Treatment Cost Impacting the Adoption Rate
    • 3.4.2 Disease Relapse in FLT3 Mutated AML
  • 3.5 Market Opportunities
    • 3.5.1 Massive Scope in Emerging Markets

4 Competitive Landscape

  • 4.1 Overview
  • 4.2 Key Developments and Strategies
    • 4.2.1 Regulatory and Legal Activities
    • 4.2.2 Product Approvals and Launches
    • 4.2.3 Partnerships and Alliances
    • 4.2.4 Other Developments
  • 4.3 Market Share Analysis (by Company), 2021
  • 4.4 Growth-Share Analysis

5 Global FLT3 inhibitors Market (by Commercialized Therapies), $Million, 2021-2032

  • 5.1 Overview
  • 5.2 Type 1 FLT3 Inhibitors
    • 5.2.1 Xospata (Gilteritinib)
    • 5.2.2 Rydapt (Midostaurin)
  • 5.3 Type 2 FLT3 Inhibitors
    • 5.3.1 Vanflyta (Quizartinib)

6 Global FLT3 inhibitors Market (by Potential Pipeline Products), $Million, 2021-2032

  • 6.1 Overview
  • 6.2 Crenolanib
    • 6.2.1 Crenolanib for Indication 1 (Newly Diagnosed FLT3 Mutated AML)
      • 6.2.1.1 Safety and Efficacy Results of Crenolanib for Newly Diagnosed FLT3 Mutated AML
    • 6.2.2 Crenolanib for Indication 2 (Relapsed/Refractory FLT3 Mutated AML)
      • 6.2.2.1 Safety and Efficacy Results of Crenolanib for Relapsed/Refractory FLT3 Mutated AML
  • 6.3 Dovitinib
    • 6.3.1 Safety and Efficacy Results of Dovitinib for Metastatic Renal Cell Carcinoma
  • 6.4 SKLB1028

7 Global FLT3 inhibitors Market (by Region), $Million, 2021-2032

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
      • 7.2.1.1 Commercialized Products
      • 7.2.1.2 Market Size and Forecast
    • 7.2.2 Canada
      • 7.2.2.1 Commercialized Products
      • 7.2.2.2 Market Size and Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Size and Forecast
    • 7.3.2 Italy
      • 7.3.2.1 Market Size and Forecast
    • 7.3.3 France
      • 7.3.3.1 Market Size and Forecast
    • 7.3.4 U.K.
      • 7.3.4.1 Market Size and Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Size and Forecast
    • 7.3.6 Rest-of-Europe
      • 7.3.6.1 Market Size and Forecast
  • 7.4 Asia-Pacific
    • 7.4.1 Japan
      • 7.4.1.1 Commercialized Products
      • 7.4.1.2 Market Size and Forecast
    • 7.4.2 China
      • 7.4.2.1 Commercialized Products
      • 7.4.2.2 Market Size and Forecast
    • 7.4.3 Rest-of-Asia-Pacific
      • 7.4.3.1 Market Size and Forecast
  • 7.5 Rest-of-the-World

8 Company Profiles

  • 8.1 Overview
  • 8.2 Cullinan Oncology, LLC
    • 8.2.1 Company Overview
    • 8.2.2 Role of Cullinan Oncology, LLC in the Global FLT3 inhibitors Market
    • 8.2.3 Key Competitors of the Company
    • 8.2.4 Key Insights about Financial Health of the Company
    • 8.2.5 Recent Developments
    • 8.2.6 Analyst's Perspective
  • 8.3 Astellas Pharma Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Role of Astellas Pharma Inc. in the Global FLT3 inhibitors Market
    • 8.3.3 Key Competitors of the Company
    • 8.3.4 Financials
    • 8.3.5 Key Insights about Financial Health of the Company
    • 8.3.6 Recent Developments
    • 8.3.7 Analyst's Perspective
  • 8.4 Allarity Therapeutics, Inc.
    • 8.4.1 Company Overview
    • 8.4.2 Role of Allarity Therapeutics, Inc. in the Global FLT3 inhibitors Market
    • 8.4.3 Key Competitors of the Company
    • 8.4.4 Recent Developments
    • 8.4.5 Analyst's Perspective
  • 8.5 AROG Pharmaceuticals, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Role of AROG Pharmaceuticals, Inc. in the Global FLT3 inhibitors Market
    • 8.5.3 Key Competitors of the Company
    • 8.5.4 Analyst's Perspective
  • 8.6 Aptose Biosciences Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Role of Aptose Biosciences Inc. in the Global FLT3 inhibitors Market
    • 8.6.3 Key Competitors of the Company
    • 8.6.4 Key Insights about Financial Health of the Company
    • 8.6.5 Recent Developments
    • 8.6.6 Analyst's Perspective
  • 8.7 Novartis International AG
    • 8.7.1 Company Overview
    • 8.7.2 Role of Novartis International AG in the Global FLT3 inhibitors Market
    • 8.7.3 Key Competitors of the Company
    • 8.7.4 Financials
    • 8.7.5 Key Insights about Financial Health of the Company
    • 8.7.6 Analyst's Perspective
  • 8.8 Daiichi Sankyo Company, Limited
    • 8.8.1 Company Overview
    • 8.8.2 Role of Daiichi Sankyo Company, Limited. in Global FLT3 inhibitors Market
    • 8.8.3 Key Competitors of the Company
    • 8.8.4 Financials
    • 8.8.5 Key Insights about Financial Health of the Company
    • 8.8.6 Recent Developments
    • 8.8.7 Analyst's Perspective
  • 8.9 CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    • 8.9.1 Company Overview
    • 8.9.2 Role of CSPC ZhongQi Pharmaceutical Technology Co., Ltd. in the Global FLT3 Inhibitors Market
    • 8.9.3 Key Competitors of the Company
    • 8.9.4 Financials
    • 8.9.5 Key Insights about Financial Health of the Company
    • 8.9.6 Analyst's Perspective
  • 8.1 FUJIFILM Pharmaceuticals U.S.A., Inc.
    • 8.10.1 Company Overview
    • 8.10.2 Role of FUJIFILM Pharmaceuticals U.S.A., Inc. in the Global FLT3 Inhibitors Market
    • 8.10.3 Key Competitors of the Company
    • 8.10.4 Analyst's Perspective
  • 8.11 Jiangsu HengRui Medicine Co., Ltd.
    • 8.11.1 Company Overview
    • 8.11.2 Role of Jiangsu HengRui Medicine Co., Ltd. in the Global FLT3 Inhibitors Market
    • 8.11.3 Key Competitors of the Company
    • 8.11.4 Financials
    • 8.11.5 Key Insights about Financial Health of the Company
    • 8.11.6 Analyst's Perspective

List of Figures

  • Figure 1: FLT3 Inhibitors Approved by U.S. Food and Drug Administration (FDA), 2015-2021
  • Figure 2: FLT3 Inhibitors Global Clinical Trials (by Phase)
  • Figure 3: Global FLT3 Inhibitors Market (by Commercialized Therapies), $Million, 2021-2032
  • Figure 4: Global FLT3 Inhibitors Market: Impact Analysis of Market Drivers and Restraints
  • Figure 5: Global FLT3 Inhibitors Market (by Potential Pipeline Products), $Million, 2021-2032
  • Figure 6: Global FLT3 Inhibitors Market (by Region), $Million, 2021-2032
  • Figure 7: Global FLT3 inhibitors Market Segmentation
  • Figure 8: Global FLT3 inhibitors Market: Research Methodology
  • Figure 9: Primary Research Methodology
  • Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 11: Step by Step Approach
  • Figure 12: Global FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 13: FLT3 Gene Mutations in AML Patients
  • Figure 14: Classification of FLT3 Inhibitors
  • Figure 15: Common and Notable Toxicities Associated with FLT3 Inhibitors
  • Figure 16: Estimated Global Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia, 2021-2032
  • Figure 17: Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in North America, 2021-2032
  • Figure 18: Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in Europe, 2021-2032
  • Figure 19: Percentage of FLT3 Mutated Acute Myeloid Leukemia Prevalence (by Country), 2021
  • Figure 20: Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in China, 2021-2032
  • Figure 21: Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in Japan, 2021-2032
  • Figure 22: Drug Diagnostic Co-Development Model
  • Figure 23: FLT3 Inhibitors Emerging Therapies: Developmental Phases
  • Figure 24: Clinical Trial Authorization for FLT3 Inhibitors
  • Figure 25: Process for Obtaining Marketing Authorization
  • Figure 26: Procedures Offered by the Food and Drug Administration (FDA) for Drugs Intended to Treat Serious Health Conditions
  • Figure 27: U.S. Food and Drug Administration Review Timeline
  • Figure 28: EMA Review Timeline
  • Figure 29: Current Reimbursement Scenario in Europe
  • Figure 30: Global Incidence of Acute Myeloid Leukemia, 2015-2019
  • Figure 31: Global Incidence of FLT3 Mutated Acute Myeloid Leukemia, 2016-2020
  • Figure 32: Number of Clinical Trials for FLT3 Inhibitors (by Major Player)
  • Figure 33: Mechanisms Responsible for Resistance to FLT3 Inhibitors
  • Figure 34: Clinical Strategies to Overcome Drug Resistance in FLT3-ITD AML
  • Figure 35: Share of Key Developments and Strategies, January 2019-June 2022
  • Figure 36: Regulatory and Legal Activities (by Company), January 2019-June 2022
  • Figure 37: Product Approvals and Launches (by Company), January 2019-June 2022
  • Figure 38: Partnerships and Alliances (by Company), January 2019-June 2022
  • Figure 39: Market Share Analysis of the Global FLT3 Inhibitors market (by Company), 2021
  • Figure 40: Growth-Share Matrix for the Global FLT3 inhibitors Market (by Company), 2021
  • Figure 41: Global FLT3 Inhibitors Market (by Commercialized Therapies), $Million, 2021-2032
  • Figure 42: Global FLT3 Inhibitors Market (by Type 1 FLT3 Inhibitors), $Million, 2021-2032
  • Figure 43: Global FLT3 Inhibitors Market (Xospata, by Type 1 FLT3 Inhibitors), $Million, 2021-2032
  • Figure 44: Global FLT3 Inhibitors Market (Rydapt, by Type 1 FLT3 Inhibitors), $Million, 2021-2032
  • Figure 45: Global FLT3 Inhibitors Market (Vanflyta, by Type 2 FLT3 Inhibitors), $Million, 2021-2032
  • Figure 46: Global FLT3 Inhibitors Market (by Potential Pipeline Products), $Million, 2021-2032
  • Figure 47: Global FLT3 Inhibitors Market (Crenolanib), $Million, 2021-2032
  • Figure 48: Crenolanib Phase III Clinical Trial Design for Newly Diagnosed FLT3 Mutated AML
  • Figure 49: Crenolanib Phase III Clinical Trial Design for Relapsed/Refractory FLT3 Mutated AML
  • Figure 50: Global FLT3 Inhibitors Market (Dovitinib), $Million, 2021-2032
  • Figure 51: Dovitinib Phase III Clinical Trial Design for Metastatic Renal Cell Carcinoma
  • Figure 52: Global FLT3 Inhibitors Market (SKLB1028), $Million, 2021-2032
  • Figure 53: SKLB1028 Phase III Clinical Trial Design for Relapsed/Refractory FLT3 Mutated AML
  • Figure 54: Global FLT3 Inhibitors Market (by Region), $Million, 2021-2032
  • Figure 55: North America FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 56: North America: Market Dynamics
  • Figure 57: North America FLT3 Inhibitors Market (by Country), $Million, 2021 and 2032
  • Figure 58: U.S. FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 59: Canada FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 60: Europe FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 61: Europe: Market Dynamics
  • Figure 62: Europe FLT3 Inhibitors Market (by Country), $Million, 2021 and 2032
  • Figure 63: Germany FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 64: Italy FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 65: France FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 66: U.K. FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 67: Spain FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 68: Rest-of-Europe FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 69: Asia-Pacific FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 70: Asia-Pacific: Market Dynamics
  • Figure 71: Asia-Pacific FLT3 Inhibitors Market (by Country), $Million, 2021 and 2032
  • Figure 72: Japan FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 73: China FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 74: Rest-of-Asia-Pacific FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 75: Rest-of-the-World FLT3 Inhibitors Market, $Million, 2021-2032
  • Figure 76: Total Number of Companies Profiled
  • Figure 77: Cullinan Oncology, LLC: Pre-Clinical and Clinical Assets
  • Figure 78: Cullinan Oncology, LLC: R&D Expenditure, $Million, 2019-2021
  • Figure 79: Astellas Pharma Inc.: Commercialized Product
  • Figure 80: Astellas Pharma Inc.: Overall Financials, $Million, 2019-2021
  • Figure 81: Astellas Pharma Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 82: Astellas Pharma Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 83: Allarity Therapeutics, Inc.: Pre-Clinical and Clinical Assets
  • Figure 84: AROG Pharmaceuticals, Inc.: Pre-Clinical and Clinical Assets
  • Figure 85: Aptose Biosciences Inc.: Pre-Clinical and Clinical Assets
  • Figure 86: Aptose Biosciences Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 87: Novartis International AG: Commercialized Product
  • Figure 88: Novartis International AG: Overall Financials, $Million, 2019-2021
  • Figure 89: Novartis International AG: Revenue (by Segment), $Million, 2019-2021
  • Figure 90: Novartis International AG: Revenue (by Region), $Million, 2019-2021
  • Figure 91: Novartis International AG: R&D Expenditure, $Million, 2019-2021
  • Figure 92: Daiichi Sankyo Company, Limited: Commercialized Product
  • Figure 93: Daiichi Sankyo Company, Limited.: Overall Financials, $Million, 2019-2021
  • Figure 94: Daiichi Sankyo Company, Limited.: Revenue (by Segment), $Million, 2019-2021
  • Figure 95: Daiichi Sankyo Company, Limited.: Revenue (by Region), $Million, 2019-2021
  • Figure 96: Daiichi Sankyo Company, Limited.: R&D Expenditure, $Million, 2019-2021
  • Figure 97: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Pre-Clinical and Clinical Assets
  • Figure 98: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Overall Financials, $Million, 2019-2021
  • Figure 99: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Revenue (by Segment), $Million, 2019-2021
  • Figure 100: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Revenue (by Region), $Million, 2019-2021
  • Figure 101: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: R&D Expenditure, $Million, 2019-2021
  • Figure 102: FUJIFILM Pharmaceuticals U.S.A., Inc.: Pre-Clinical and Clinical Assets
  • Figure 103: Jiangsu HengRui Medicine Co., Ltd.: Pre-Clinical and Clinical Assets
  • Figure 104: Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, $Million, 2019-2021
  • Figure 105: Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, $Million, 2019-2021

List of Tables

  • Table 1: Mechanisms of Resistance of FLT3-Mutated AML Cells to FLT3 Inhibitors
  • Table 2: Prominent CDx Tests for FLT3 Mutated AML
  • Table 3: Emerging Phase III FLT3 Therapeutics Pipeline
  • Table 4: Annual Cost of Approved FLT3 Inhibitors in the U.S.
  • Table 5: Reimbursement Scenario of Approved FLT3 Inhibitors in the U.S.
  • Table 6: Likert Scale
  • Table 7: Impact Analysis of Market Drivers
  • Table 8: Impact Analysis of Market Restraints
  • Table 9: Approved FLT3 Inhibitors for FLT3 Mutated AML
  • Table 10: Approved FLT3 Inhibitors Products in Developed Nations
  • Table 11: Commercialized Products in the Global FLT3 Inhibitors Market
  • Table 12: Potential Pipeline Products to Global FLT3 Inhibitors Market
  • Table 13: List of Selective Commercialized FLT3 Inhibitors in the U.S.
  • Table 14: List of Selective Commercialized FLT3 Inhibitors in Canada
  • Table 15: List of Selective Commercialized FLT3 Inhibitors in Europe
  • Table 16: List of Selective Commercialized FLT3 Inhibitors in Japan
  • Table 17: List of Selective Commercialized FLT3 Inhibitors in China